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THE EFFECT OF DONOR CYTOMEGALOVIRUS (CMV) SEROLOGIC STATUS
ON CMV REACTIVATION AND SURVIVAL IN PATIENTS UNDERGOING
ALLOGENIC STEM CELL TRANSPLANTATION
Vega, J.1, Vatca, M.2, Mikulandric, N.3, Neme, K.3, Hanbali, A.1,
Janakiraman, N.1 1Henry Ford Hospital, Detroit, MI; 2Henry Ford Hos-
pital, Detroit, MI; 3Henry Ford Hospital, Detroit, MI
Background:Cytomegalovirus continues to be a common cause of
morbidity and mortality after allogenic hematopoietic stem cell trans-
plantation (SCT) despite major advances in diagnostic techniques and
antiviral prophylactic strategies. Recipient CMV-seropositivity is
a major predictor of adverse outcomes. Data regarding the effect of
the donor serologic status on recipient outcomes are limited.
Methods:To investigate this topic, the records of CMV-seropos-
itive patients who underwent allogenic SCT in our institution be-
tween 1995 and 2005 were reviewed. Patients with unknown CMV
status, or whose donors were of unknown CMV status were ex-
cluded. The studied outcomes included CMV reactivation, CMV
disease, and 100-day mortality. CMV reactivation was defined as
two consecutive positive CMV polymerase chain reaction (PCR)
analysis without evidence of end-organ damage. CMV disease was
defined as positive CMV PCR with evidence of retinitis, pneumoni-
tis, enteritis, or myelosuppression.
Results:Ninety eight CMV-seropositive patients who underwent
allogenic SCT were identified. Among them, 61 had a CMV-sero-
positive donor, and 37 had a CMV-seronegative donor. Median
follow-up time was 10.4 months. There were no significant differ-
ences in the studied outcomes. CMV reactivation occurred in 20
(54%) patients in the CMV-seronegative donor group, and 32
(52%) patients in the CMV-seropositive donor group. CMV disease
occurred in 11 (30%) patients in theCMV-seronegative donor group
and 14 (23%) in the CMV-seropositive donor group. The 100-day
mortality was 27% in the CMV-seronegative donor group and
18% in the CMV-seropositive donor group.
CMV (2) CMV (1)
Donor (N537) Donor (N561) p-valueCMV Reactivation 20 (54%) 32 (52%) 0.878
CMV Disease 11 (30%) 14 (23%) 0.455
100-day Mortality 10 (27%) 11 (18%) 0.293A secondary aim of establishing risk factors for CMV reactivation
was performed. Age and antithymocyte globulin (ATG) prophylaxis
were observed to be significant predictors for CMV reactivation.
More specifically, for every year increase in age, a 1.051 increase in
oddsofCMVreactivationwasobserved.Further, thosewhodidnot re-
ceive ATG prophylaxis were observed to be 0.229 times less likely to
experience CMV reactivation, compared to those who received it.
Conclusions: Donor CMV serologic status did not significantly
affect the incidence of CMV reactivation, CMV disease, or 100-
day mortality in CMV-seropositive patients undergoing allogenic
SCT in this single institution study.
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BIOAVAILABILITY OF MARIBAVIR WHOLE TABLET IS UNAFFECTED BY
CRUSHING THE TABLET
Canas, S.M.1, Johnson, J.2, Gelone, S.2, Gomez, A.2, Schumacher, M.2,
Villano, S.2 1Prism Research, St. Paul, MN; 2ViroPharma Incorporated,
Exton, PA
Background: Maribavir (MBV), an orally bioavailable antiviral
drug with a novel mechanism of action against human cytomegalo-
virus (CMV) and a favorable tolerability profile, is currently in devel-
opment for prevention of CMV disease in transplant patients.
Immunosuppressed patients are often unable to swallow a whole tab-
let; therefore, the possibility exists that individuals may need to crush
the tablet in order to administer MBV. This study was designed to
determine the relative bioavailability of the MBV 100 mg tablet ad-
ministered whole or crushed in a solution.
Methods: This was a single-dose, open-label, randomized, cross-
over study in 15 healthy subjects (8M, 7F) with a mean age of 32
years. Subjects received 100mgMBVunder fasting conditions either
as a whole tablet taken with 240 mL water or crushed in a volume of
240 mL water with a 7- to 14-day washout period between doses. Afull pharmacokinetic (PK) evaluation was performed over the 24
hours following each administration. Standard safety monitoring
was performed.
Results:Oral MBV 100 mg was generally well tolerated when ad-
ministered either as a whole or crushed tablet in solution. The most
frequently reported treatment-emergent events were taste distur-
bance and headache, each of which occurred in five (33%) subjects.
Mean (SD) PK parameters for the crushed and whole tablet formu-
lations are shown below with results from ANOVA.
Ratio of
Crushed
TabletWhole
TabletGeometric
Means (90%CI)Tmax (h) 1.0 (0.3) 1.1 (0.3) Not statistically differentaCmax (mcg/mL) 5.78 (2.01) 5.83 (1.92) 0.983 (0.876, 1.102)
t1⁄2 (h) 3.66 (1.20) 3.86 (1.35) 0.959 (0.815, 1.129)
AUC(0-inf) (mcg*h/mL) 24.7 (9.63) 26.0 (10.7) 0.960 (0.892, 1.033)
Vz/F (L) 22.9 (8.62) 22.6 (6.54) 0.999 (0.878, 1.136)
CL/F (L/h) 4.49 (1.33) 4.36 (1.51) 1.042 (0.968, 1.121)ap50.142.
Conclusions: Systemic exposure to MBVwas equivalent after ad-
ministration of either the whole tablet or the crushed tablet in solu-
tion. Crushing MBV tablets is a viable option for administration of
MBV to patients who are unable to swallow whole tablets.
302
CLOFARABINE MELPHALAN AND THIOTEPA FOLLOWED BY UNMODI-
FIED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
FOR THE TREATMENT OF HIGH-RISK OR ADVANCED ACUTE LEUKEMIA
Boulad, F., Kernan, N.A., Prockop, S.E., Scaradavou, A., Small, T.N.,
Jakubowski, A., Papadopoulos, E., Perales, M.A. Memorial Sloan-Ketter-
ing Cancer Center, New York, NY
High-risk or advanced acute leukemias are associated with poor
outcome even with the use of HSCT. We have developed a phase
I/II protocol using Clofarabine in combination with melphalan
(Mel) and thiotepa (Thio) followed by unmodified HSCT for the
treatment of patients (pts) with high-risk leukemias. To date, 11
pts were treated. There were 6males and 5 females aged 1.3–39 years
(med 6.5). Cytoreduction consisted of CLO 20 mg/m2/d X 5 (dose
level 1), Thio 10mg/Kg/dX 1 andMel 70mg/m2/d X 2.GvHDpro-
phylaxis consisted of tacrolimus and mycophenolate mofetil (MMF).
All 11 pts had acute lymphoblastic leukemia (ALL) with the follow-
ing stages at HSCT: Very high risk Infant ALL in first complete re-
mission (CR) (N5 2) or CR2 (N5 1), ALL in CR2 (N5 1), ALL in
CR3 (N 5 6), and ALL in second refractory relapse (N 5 1). This
was a first HSCT for 4pts, a second SCT for 6 pts and third SCT
for 1 pt, with time from HSCT1 to HSCT2 being 8–60 months
(mo) for those 7 pts. Donors were HLA-matched siblings (N 5 5)
or HLA matched (N5 3) or mismatched (N5 3) unrelated donors.
Unmodified grafts included bone marrow (N5 6), peripheral blood
(N5 4) or double cord blood (n5 1) stem cells. All 11 pts engrafted.
Toxicity of the cytoreduction included elevation of hepatic transam-
inases in 6 of 11 pts (AST 5–19 fold and ALT 7–16 fold), with a sub-
sequent normalization in all pts. During the period of liver enzyme
elevation, chemotherapy was continued for 2 pts and held for 2
days in 4 pts. One pt (in relapse and with a history of hepatic steato-
sis) developed hepatic veno-occlusive disease (VOD). Mucositis was
at acceptable grade 1–2 levels. There was no other major regimen re-
lated toxicity. Pts were discharged at a median day136 post HSCT.
With a follow-up of 2–23 mo (median 8 mo), 7 of the 11 pts are alive,
disease-free. Three pts relapsed and died subsequently of disease and
one pt died of VOD. Four pts, all recipients of unrelated donor SCT
(including all 3 mismatched donors) developed Grade 1 (N 5 2),
Grade 2 (N 5 1) or Grade 3 (N 5 1) acute GvHD) of whom 2
developed chronic GvHD. Immune reconstitution was rapid with
absolute CD4 counts .200 cells/mcl at 1–3 mo for 7 pts and PHA
responses of 100% of normal at 1–3 mo post HSCT for 5 pts.
This cytoreductive regimen represents a promising approach for
the transplantation of patients with high risk acute leukemias. It ap-
pears to be well tolerated for pts requiring a second SCT and is also
associated with rapid immune recovery.
